BassieNL schreef op 15 jun 2019 om 09:00:
Over voortgang Fase 3.
Dit is wat bekend is over de aantallen patienten.
4-12-2017 First patient
enrolled in Phase 3 trial
12-10-2018 The Company has now enrolled 22 patients
and has 14 sites open in 7 countries. Kiadis Pharma expects to have over 20 sites open by the end of 2018, including several US sites. An interim analysis of the Phase 3 study is expected in the second half of 2020.
Uit de prospectus van 31-5-2019 blijkt:
At the end of March 2019, 17 clinical sites were
open for recruitment and 33 patients
had been enrolled.